Supira Medical Secures $120M Oversubscribed Series E Financing and Completes Enrollment of SUPPORT I Early Feasibility Study in the United States
Summary
"This significant capital raise underscores the teams tremendous progress as we look forward to exciting opportunities ahead of us to improve clinical outcomes for both HRPCI and cardiogenic shock patients." "We believe there is a massive unmet need for next-generation ventricular support devices to promote myocardial recovery and improve peripheral organ perfusion in HRPCI and CS patients," stated Dr. Shen. "The Supira team has built a strong clinical foundation to further validate their advanced low-profile, high flow technology platform in two important segments of interventional heart failure, and we are pleased with their excellent progress bringing this therapy closer to market." The prospective, single-arm clinical study evaluated the safety and feasibility of Supiras innovative pVAD in patients undergoing HRPCI. pVADs are important for supporting cardiovascular function during HRPCI, particularly in patients with complex coronary anatomy, compromised hemodynamics, and multiple comorbidities.